Skip to content

Effects of WB-EMS and Protein Supplementation on LBM Maintenance During Intended Weight Loss

Effects of Whole-body Electromyostimulation (WB-EMS), Physical Activity and Protein Supplementation on Lean Body Mass Maintenance During Caloric Restriction and Physical Activity Induced Weight Loss. A Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03746977
Enrollment
30
Registered
2018-11-20
Start date
2018-01-25
Completion date
2018-12-01
Last updated
2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Obesity, Obesity, Overweight

Keywords

exercise, electromyostimulation, protein, weight reduction

Brief summary

The present study aimed to determine the effect of different interventions on lean body mass maintenance under weight loss conditions in overweight and obese premenopausal women. Three study groups were implemented: (1) Protein supplementation (only) group (2) Protein supplementation and walking intervention (3) Protein supplementation, walking and WB-EMS-application. All protocols were applied for 16 week of intervention. A energy deficit of 500 kcal/d was intended however while group (1) focus consistently on energy restriction (500 kcal/d), in group (2) and (3) a combined physical activity (i.e. walking with a volume representing 250 kcal/d) and energy restriction (250 kcal/d) protocol was applied. Total protein uptake including protein supplementation was calculated to average around 1.2 g/kg body mass per day in groups (1) and 1.5 g/kg body mass/d in group (2) and (3). WB-EMS was applied 1.5x 20 min/week (i.e. each Tuesday and every second Thursday). Primary study endpoint was LBM as determined by Dual Energy x-Ray Absorptiometry.

Interventions

DIETARY_SUPPLEMENTProtein

Protein supplementation 1.2 or 1.5 g/kg body mass/d

BEHAVIORALWalking

Walking with a volume corresponding to 250 kcal/d

WB-EMS application 1.5x 20 min/week

Sponsors

University of Erlangen-Nürnberg Medical School
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Outcome assessors were not aware of the status of the participants and were not allowed to ask correspondingly. Each of the participants were blinded according to the treatment and intervention. Participants of the three study groups were not in contact.

Intervention model description

Randomized controlled parallel group design with 3 study arms

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* premenopausal women 25-50 years old * overweight/obesity (body fat rate equal or higher 30%)

Exclusion criteria

* medication and diseases affecting muscle and fat metabolism * pregnant or parturition \< 6 months * any condition or medication that prevent proper physical activity or WB-EMS application * holidays equal or more than 1 week during the intervention period * other interventions with impact on the primary and core secondary outcome (i.e. body fat parameters) started during the last year.

Design outcomes

Primary

MeasureTime frameDescription
Lean body masschanges from baseline to 16 week follow-upFat and bone free total body mass in kg

Secondary

MeasureTime frameDescription
Total Body Fat Ratechanges from baseline to 16 week follow-upPercent Total Body Fat Rate
Appendicular Skeletal Muscle Masschanges from baseline to 16 week follow-upLean Body Mass of the upper and lower limbs in kg
Total Body Fatchanges from baseline to 16 week follow-upTotal Body Fat in kg
Trunk fatchanges from baseline to 16 week follow-upTotal trunk fat in kg
Metabolic Syndrome Z-Scorechanges from baseline to 16 week follow-upSummarized Z-Score that included Z-Scores of blood lipids, lipoproteins, glucose, resting blood pressure and waist circumference. Cut-offs based on the definition of the International Diabetes Federations
Visceral Body Fatchanges from baseline to 16 week follow-upTotal visceral body fat in kg

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026